Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06895512 | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | not yet recruiting | Phase 3 | 386 | Shanghai Henlius BiotechINDUSTRY | 1 |
| Mar 26, 2025 |
| clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06888752 | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 35 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06888856 | Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients(MMOMICS) | not yet recruiting | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06890091 | Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma(CAR-TIGUE) | not yet recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06757478 | A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma | not yet recruiting | — | 30 | First Affiliated Hospital of Ningbo UniversityNETWORK | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05662904 | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML(GALAXY33) | not yet recruiting | Phase 1 | 12 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06876701 | The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults | not yet recruiting | Early Phase 1 | 10 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06667973 | Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 80 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06847529 | Systemic Inflammatory Markers in B-cell Neoplasm | not yet recruiting | — | 70 | Assiut UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06863441 | The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma | not yet recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865443 | Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Mar 7, 2025 | clinicaltrials |
| NCT06861348 | Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT(ZJU-HSCT-INO) | not yet recruiting | Phase 2 | 23 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06848270 | Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care | not yet recruiting | N/A | 50 | Universidade do PortoOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06845241 | Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 68 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06841952 | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia | not yet recruiting | N/A | 158 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06837389 | Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors | not yet recruiting | Early Phase 1 | 18 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06654206 | Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients | not yet recruiting | Early Phase 1 | 40 | University of SalamancaOTHER | 0 | Feb 19, 2025 | clinicaltrials |
| NCT06825845 | Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy | not yet recruiting | — | 1,500 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 0 | Feb 13, 2025 | clinicaltrials |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg(BE-Dasatinib) | not yet recruiting | Phase 4 | 46 | Centro de Atencion e Investigacion MedicaNETWORK | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06817759 | Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer | not yet recruiting | N/A | 60 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06799676 | A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 42 | Fuling ZhouOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06665737 | Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients(G-CSF in NHL) | not yet recruiting | Phase 4 | 126 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06714071 | Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients | not yet recruiting | — | 80 | Assiut UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06797648 | Epidemiology of Infection in Acute Myeloid Leukemia (AML)(EPIAMLINF) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06790719 | Paediatric Breakthrough Pain Assessment(BEACON) | not yet recruiting | — | 210 | University of SouthamptonOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06792630 | A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients | not yet recruiting | N/A | 98 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 24, 2025 | clinicaltrials |
| NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. | not yet recruiting | Early Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785870 | EVAluation of Erythrocytosis PRospEctive Cohort STudy(EVEREST) | not yet recruiting | — | 1,500 | Cyrus HsiaOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783478 | NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial(NKLMA) | not yet recruiting | Phase 2 | 98 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06754540 | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | not yet recruiting | Phase 2 | 51 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06777264 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1(JUVENTAS-ALL05) | not yet recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06761911 | BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | not yet recruiting | Phase 4 | 100 | Xiuhua SunOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06758726 | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06757894 | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06753279 | Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs) | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Dec 31, 2024 | clinicaltrials |
| NCT06643195 | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia | not yet recruiting | N/A | 358 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746571 | Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients | not yet recruiting | N/A | 100 | Sohag UniversityOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06747299 | The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06744894 | SIL as Maintenance Therapy in Multiple Myeloma | not yet recruiting | Phase 2 | 50 | Navy General Hospital, BeijingOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT06741813 | Allo-HSCT vs ASCT in Adult T-LBL(TROPHY-NHL01) | not yet recruiting | N/A | 230 | Peking University People's HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06742138 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | not yet recruiting | Phase 3 | 284 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2025source: clinicaltrials